Method: Antibody preparations were evaluated by SARS-CoV-2 pseudovirus neutralization assay (PsVNA) using WA-1 strain, UK variant (B.1.1.7 with
spike mutations: H69-V70del,
Y144del,
N501Y,
A570D,
D614G,
P681H,
T716I,
S982A, and
D1118H), SA variant (B.1.351 strain with
spike mutations
L18F,
D80A,
D215G, L242-244del,
R246I,
K417N,
E484K,
N501Y,
D614G, and